Rosa Viana

Rosa Viana

Auto-generated profile, based on publicly available information

Rosa Viana

Instituto de Biomedicina de Valencia, CSIC and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Valencia, Spain

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2000 in Molecular Microbiology
Verified
Journal Article
Closed access
PDF file
RVRosa Viana
Rosa Viana
VMVicente Monedero
Vicente Monedero
VDValérie Dossonnet
Valérie Dossonnet
CVChristian Vadeboncoeur
Christian Vadeboncoeur
Gaspar Pérez MartínezGaspar Pérez Martínez
Gaspar Pérez Martínez
JDJosef Deutscher
Josef Deutscher

1 May 2008 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
RVRosa Viana
Rosa Viana
CACarmen Aguado
Carmen Aguado
IEInmaculada Esteban
Inmaculada Esteban
DMDaniel Moreno-Andrés
Daniel Moreno-Andrés
Benoit ViolletBenoit Viollet
Benoit Viollet
PSPascual Sanz
Pascual Sanz

1 February 2018 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
CRCarla Rubio-Villena
Carla Rubio-Villena
RVRosa Viana
Rosa Viana
JBJose Bonet
Jose Bonet
MGMaría Adelaida García-Gimeno
María Adelaida García-Gimeno
MPMarta Casado Pinna
Marta Casado Pinna
PSPascual Sanz
Pascual Sanz
Lafora disease (LD) is a fatal form of progressive myoclonus epilepsy characterized by the accumulation of insoluble poorly branched glycogen-like inclusions named Lafora bodies (LBs) in the brain and peripheral tissues. In the brain, since its first discovery in 1911, it was assumed that these glycogen inclusions were only present in affected neurons. Mouse models of LD have been obtained recently, and we and others have been able to report the accumulation of glycogen inclusions in the brain of LD animals, what recapitulates the hallmark of the disease. In this work we present evidence indicating that, although in mouse models of LD glycogen inclusions co-localize with neurons, as originally established, most of them co-localize with astrocytic markers such as glial fibrillary acidic protein (GFAP) and glutamine synthase. In addition, we have observed that primary cultures of astrocytes from LD mouse models accumulate higher levels of glycogen than controls. These results suggest that astrocytes may play a crucial role in the pathophysiology of Lafora disease, as the accumulation of glycogen inclusions in these cells may affect their regular functionality leading them to a possible neuronal dysfunction.

4 April 2016 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
ILIrene López-González
Irene López-González
RVRosa Viana
Rosa Viana
PSPascual Sanz
Pascual Sanz
Isidro FerrerIsidro Ferrer
Isidro Ferrer
Lafora progressive myoclonus epilepsy (Lafora disease, LD) is a fatal rare autosomal recessive neurodegenerative disorder characterized by the accumulation of insoluble ubiquitinated polyglucosan inclusions in the cytoplasm of neurons, which is most commonly associated with mutations in two genes: EPM2A, encoding the glucan phosphatase laforin, and EPM2B, encoding the E3-ubiquitin ligase malin. The present study analyzes possible inflammatory responses in the mouse lines Epm2a −/− (laforin knock-out) and Epm2b −/− (malin knock-out) with disease progression. Increased numbers of reactive astrocytes (expressing the GFAP marker) and microglia (expressing the Iba1 marker) together with increased expression of genes encoding cytokines and mediators of the inflammatory response occur in both mouse lines although with marked genotype differences. C3ar1 and CxCl10 messenger RNAs (mRNAs) are significantly increased in Epm2a −/− mice aged 12 months when compared with age-matched controls, whereas C3ar1, C4b, Ccl4, CxCl10, Il1b, Il6, Tnfα, and Il10ra mRNAs are significantly upregulated in Epm2b −/− at the same age. This is accompanied by increased protein levels of IL1-β, IL6, TNFα, and Cox2 particularly in Epm2b −/− mice. The severity of inflammatory changes correlates with more severe clinical symptoms previously described in Epm2b −/− mice. These findings show for the first time increased innate inflammatory responses in a neurodegenerative disease with polyglucosan intraneuronal deposits which increase with disease progression, in a way similar to what is seen in neurodegenerative diseases with abnormal protein aggregates. These findings also point to the possibility of using anti-inflammatory agents to mitigate the degenerative process in LD.

4 November 2016
Verified
Book Chapter
Closed access
PDF file
PSPascual Sanz
Pascual Sanz
RVRosa Viana
Rosa Viana
MGMaría Adelaida García-Gimeno
María Adelaida García-Gimeno

1 June 2016 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
CMCarmen Munoz-Ballester
Carmen Munoz-Ballester
ABArnaud Berthier
Arnaud Berthier
RVRosa Viana
Rosa Viana
PSPascual Sanz
Pascual Sanz